Posts by hzhang

King of Prussia, PA – September 23, 2025 – SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable…

New York, NY – September 9, 2025 – Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD) gathered on September 6, 2025,…

Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance…

First Patient Dosing Expected in Q1 2026   Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers   King of Prussia, PA – August 11, 2025 –…